We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Isogenica Renews Research Collaboration with AstraZeneca

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Isogenica Ltd has announced that it has entered into a research collaboration with AstraZeneca.

The research programme centres on the use of Isogenica’s CIS display technology for the discovery of peptides which are specific for, and biologically active against, targets provided by AstraZeneca.

The collaboration builds upon a pilot study that was initiated by the parties in 2004.

Isogenica’s CIS display technology is designed to provide a means of identifying peptides and polypeptides that bind with high affinity and fine specificity to any given molecular target.

CIS display can be widely applied to the drug discovery and development process as well as to the discovery and development of non-therapeutic products.

"We are very pleased to welcome back AstraZeneca as a returning customer," said Dr Kevin FitzGerald, Isogenica’s CEO.

"We look forward to re-establishing the excellent working relationship that was a key feature of our previous collaboration."

Dr Paul Leff, VP of Discovery Enabling Capabilities and Sciences at AstraZeneca said, "We are very pleased to be working with Isogenica again."

"They have a robust technology that can provide significant opportunities within the lead generation and target validation phases of the drug discovery process."